Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities

Article content

HIGHLIGHTS

Article content

Article content

Article content

Article content

PARMA, Italy — Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 (“H1 2026”).

Article content

Article content

Performance across therapeutic areas and regions

Article content

Chiesi reported revenues of

Article content

€1.89 billion

Article content

, representing growth of

Article content

+3.6% at constant exchange rates (CER)

Article content

compared with H1 2025. These results do not include the impact of the recent acquisition of KalVista Pharmaceuticals.

Article content

The Group’s growth is supported by continued expansion of its global rare diseases area (+€45m; +9.9% @CER), and sustained performance in neonatology and specialty care therapeutic areas (+6.5% @CER). The respiratory health area remains broadly stable (-0.8% @CER) fueled by the strong growth in our inhaled triple therapy portfolio.

Article content

Driven by the ongoing execution of its international growth strategy, Chiesi continued to expand its presence in key markets, with particularly strong momentum in the United States (+9.6% @CER), while maintaining resilient performance across Europe (+0.9% @CER) and a continuous development of the remaining geographies (+5.5% @CER). EBITDA margin was 29.4%, reflecting continued strong profitability, disciplined resource allocation and operational focus. The Group also maintained solid cash generation from operations, enabling continued investment in its research pipeline, manufacturing capabilities, and strategic acquisitions.

Article content

Continued commitment to innovation

Article content

The focus on innovation remains central to Chiesi’s strategy. During the first half of 2026, the Group invested

Article content

€426 million

Article content

in Research & Development, representing approximately

Article content

22.5% of revenues

Article content

.

Article content

Investments were focused on advancing the pipeline across respiratory health, rare diseases and specialty care, while also supporting the development of the Group’s Carbon Minimal Inhaler (CMI) platform and strengthening the industrial capabilities required to support its future rollout. This included the strategic partnership with Bespak, aimed at delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients.

Article content

During the first half of the year, Chiesi also completed the acquisition of KalVista Pharmaceuticals, a US-based pharmaceutical company with a differentiated oral, on demand treatment for hereditary angioedema (HAE), further strengthening its global rare disease platform and pipeline in areas of high unmet medical need.

Article content

Article content

Creating positive impact beyond healthcare: Chiesi’s Economic Footprint

Article content

Chiesi’s impact extends well beyond the healthcare solutions it delivers to patients. According to its recent Economic Footprint assessment conducted with PwC Italy (part of an international professional services network), in 2025 the Group generated approximately

Article content

€6 billion in total GDP worldwide

Article content

, supported

Article content

56,488 jobs

Article content

, and contributed nearly

Article content

€2 billion in taxes and public revenues

Article content

across the countries in which it operates.

Article content

As a European-headquartered company with innovation deeply rooted across the region, Chiesi generated €4.1 billion in total GDP across Europe, supported almost 30,000 jobs and contributed approximately €1.4 billion in taxes and public revenues. The study also found that Europe accounted for 78% of Chiesi’s global R&D investment and 60% of all suppliers engaged by the Group, highlighting the region’s central role in driving innovation, employment and economic growth.

Article content

At the same time, Chiesi continues to expand its contribution in key international markets, generating more than €1.1 billion in GDP impact in the U.S. while supporting almost 4,000 jobs in the country. It also contributes €800 million in GDP impact across China, Brazil, Australia, Mexico and rest of the world, and more than 22,000 jobs across these markets.

Article content

These findings demonstrate Chiesi’s long-standing commitment to strengthening the overall healthcare ecosystem and creating value for patients, healthcare systems, local communities and economies across the world.

Article content

Jean Marc Bellemin, CFO and Interim CEO of Chiesi Group, commented:

Article content

“Our first-half results for 2026 reflect the resilience of our strategy and the strength of our global footprint. As we continue to deliver a solid performance, we remain focused on innovation, sustainable growth, and creating long-term value for patients, society and the environment. The acquisition of KalVista further strengthens our position in rare diseases and expands our presence in the U.S., while our Economic Footprint study illustrates Chiesi’s broader contribution to the economies and communities in which we operate. We remain focused on combining sustainable growth with continued innovation and long-term value creation for patients and society.”

Article content

About Chiesi Group

Article content

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.